MicroRNA Regulators of Anxiety and Metabolic Disorders

Trends in Molecular Medicine

Volumn 22, Issue 9, 2016, Pages 798-812

  Meydan, Chanan ^a,b   Shenhar Tsarfaty, Shani ^a,c   Soreq, Hermona ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

anxiety; cholinergic; metabolic disorder; miRNAs; obesity

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; C REACTIVE PROTEIN; CHLOROTRIANISENE; CHOLINESTERASE; INTERLEUKIN 6; MICRORNA; MICRORNA 124; MICRORNA 132; STAT3 PROTEIN; TUMOR NECROSIS FACTOR;

ANXIETY; ANXIETY DISORDER; AUTONOMIC NERVOUS SYSTEM; DISEASE ASSOCIATION; HUMAN; METABOLIC SYNDROME X; METABOLISM; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; ANIMAL; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLIC DISORDER; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ANIMALS; ANXIETY; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; METABOLIC DISEASES; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 84990955534     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.07.001     Document Type: Review

References (114)

1. 1 Ford, E.S., Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28 (2005), 2745–2749.
2. 2 O'Neill, S., O'Driscoll, L., Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes. Rev. 16 (2015), 1–12.
3. 3 Ridker, P.M., et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352 (2005), 20–28.
4. 4 Christian, P., Su, Q., MicroRNA regulation of mitochondrial and ER stress signaling pathways: implications for lipoprotein metabolism in metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 307 (2014), E729–E737.
5. 5 Caputa, G., Schaffer, J.E., RNA regulation of lipotoxicity and metabolic stress. Diabetes 65 (2016), 1816–1823.
6. 6 Uchida, S., et al. Early life stress enhances behavioral vulnerability to stress through the activation of REST4-mediated gene transcription in the medial prefrontal cortex of rodents. J. Neurosci. 30 (2010), 15007–15018.
7. 7 Rinaldi, A., et al. Stress induces region specific alterations in microRNAs expression in mice. Behav. Brain Res. 208 (2010), 265–269.
8. 8 Meerson, A., et al. Changes in brain microRNAs contribute to cholinergic stress reactions. J. Mol. Neurosci. 40 (2010), 47–55.
9. 9 Vreugdenhil, E., et al. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology 150 (2009), 2220–2228.
10. 10 Vo, N., et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc. Natl. Acad. Sci. U.S.A. 102 (2005), 16426–16431.
11. 11 Malan-Muller, S., et al. Big effects of small RNAs: a review of microRNAs in anxiety. Mol. Neurobiol. 47 (2013), 726–739.
12. 12 Sestan-Pesa, M., Horvath, T.L., Metabolism and mental illness. Trends Mol. Med. 22 (2016), 174–183.
13. 13 Kessler, R.C., et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol. Psichiatr. Soc. 18 (2009), 23–33.
14. 14 Joels, M., Baram, T.Z., The neuro-symphony of stress. Nat. Rev. Neuroscie. 10 (2009), 459–466.
15. 15 Thayer, J.F., et al. Autonomic characteristics of generalized anxiety disorder and worry. Biol. Psychiatry 39 (1996), 255–266.
16. 16 Beske, S.D., et al. Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 282 (2002), H630–H635.
17. 17 Peterson, H.R., et al. Body fat and the activity of the autonomic nervous system. N. Engl. J. Med. 318 (1988), 1077–1083.
18. 18 Carnethon, M.R., et al. Influence of autonomic nervous system dysfunction on the development of type 2 diabetes: the CARDIA study. Diabetes care 26 (2003), 3035–3041.
19. 19 Sharma, S., Fulton, S., Diet-induced obesity promotes depressive-like behaviour that is associated with neural adaptations in brain reward circuitry. Int. J. Obes. 37 (2013), 382–389.
20. 20 Uretsky, S., et al. Obesity paradox in patients with hypertension and coronary artery disease. Am. J. Med. 120 (2007), 863–870.
21. 21 Jakobsson, J., et al. KAP1-mediated epigenetic repression in the forebrain modulates behavioral vulnerability to stress. Neuron 60 (2008), 818–831.
22. 22 Dalgaard, K., et al. Trim28 haploinsufficiency triggers bi-stable epigenetic obesity. Cell 164 (2016), 353–364.
23. 23 Karpe, F., Lindgren, C.M., Obesity – on or off?. N. Engl. J. Med. 374 (2016), 1486–1488.
24. 24 Soreq, H., Checks and balances on cholinergic signaling in brain and body function. Trends Neurosci. 38 (2015), 448–458.
25. 25 Lim, L.P., et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433 (2005), 769–773.
26. 26 Hanin, G., et al. Competing targets of microRNA-608 affect anxiety and hypertension. Hum. Mol. Genet. 23 (2014), 4569–4580.
27. 27 Lindenblatt, C., et al. IkappaBzeta expression is regulated by miR-124a. Cell Cycle 8 (2009), 2019–2023.
28. 28 Shaked, I., et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 31 (2009), 965–973.
29. 29 Krichevsky, A.M., et al. Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem cells 24 (2006), 857–864.
30. 30 O'Connor, R.M., et al. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol. Psychiatry 17 (2012), 359–376.
31. 31 Issler, O., et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 83 (2014), 344–360.
32. 32 Codocedo, J.F., et al. Are microRNAs the molecular link between metabolic syndrome and Alzheimer's disease?. Mol. Neurobiol. 53 (2016), 2320–2338.
33. 33 Arner, P., Kulyte, A., MicroRNA regulatory networks in human adipose tissue and obesity. Nat. Rev. Endocrinol. 11 (2015), 276–288.
34. 34 Arner, E., et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes 61 (2012), 1986–1993.
35. 35 Strum, J.C., et al. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol. Endocrinol. 23 (2009), 1876–1884.
36. 36 Avena, N.M., et al. Sucrose sham feeding on a binge schedule releases accumbens dopamine repeatedly and eliminates the acetylcholine satiety response. Neuroscience 139 (2006), 813–820.
37. 37 Wang, G.J., et al. Brain dopamine and obesity. Lancet 357 (2001), 354–357.
38. 38 Zhu, Y., et al. Joint association of nicotinic acetylcholine receptor variants with abdominal obesity in American Indians: the Strong Heart Family Study. PloS ONE, 9, 2014, e102220.
39. 39 Joshi, P.K., et al. Variants near CHRNA3/5 and APOE have age- and sex-related effects on human lifespan. Nat. Commun., 7, 2016, 11174.
40. 40 Lima, J.K., et al. 1914G variant of BCHE gene associated with enzyme activity, obesity and triglyceride levels. Gene 532 (2013), 24–26.
41. 41 Dantas, V.G., et al. Obesity and variants of the GHRL (ghrelin) and BCHE (butyrylcholinesterase) genes. Genet. Mol. Biol. 34 (2011), 205–207.
42. 42 Saccone, S.F., et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16 (2007), 36–49.
43. 43 Wang, J.C., et al. Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol. Psych. 14 (2009), 501–510.
44. 44 Ehringer, M.A., et al. Association of the neuronal nicotinic receptor beta2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am. J. Med. Genet. B Neuropsychiatr. genet. 144B (2007), 596–604.
45. 45 Li, M.D., et al. Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum. Mol. Genet. 14 (2005), 1211–1219.
46. 46 Sternberg, E.M., Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6 (2006), 318–328.
47. 47 de Jonge, W.J., et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2–STAT3 signaling pathway. Nat. immunol. 6 (2005), 844–851.
48. 48 Wang, H., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421 (2003), 384–388.
49. 49 Lotze, M.T., Tracey, K.J., High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. rev. Immunol. 5 (2005), 331–342.
50. 50 Wang, H., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10 (2004), 1216–1221.
51. 51 Maharshak, N., et al. MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease. Inflamm. Bowel Dis. 19 (2013), 1346–1353.
52. 52 Shenhar-Tsarfaty, S., et al. Weakened cholinergic blockade of inflammation associates with diabetes-related depression. Mol. Med., 22, 2016, 10.2119/molmed.2016.00067 Published online March 28, 2016.
53. 53 Shenhar-Tsarfaty, S., et al. Fear and C-reactive protein cosynergize annual pulse increases in healthy adults. Proc. Nat. Acad. Sci. U.S.A. 112 (2015), E467–E471.
54. 54 Tracey, K.J., Understanding immunity requires more than immunology. Na. Immunol. 11 (2010), 561–564.
55. 55 Pullan, R.D., et al. Transdermal nicotine for active ulcerative colitis. N. Engl. J. Med. 330 (1994), 811–815.
56. 56 Lakhan, S.E., Kirchgessner, A., Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J. Transl. Med., 9, 2011, 129.
57. 57 Borovikova, L.V., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000), 458–462.
58. 58 Sotornik, R., et al. Regulation of blood flow in adipose tissue: involvement of the cholinergic system. Am. J. Physiol. Endocrino. Metab. 309 (2015), E55–E62.
59. 59 Cancello, R., et al. The nicotinic acetylcholine receptor alpha7 in subcutaneous mature adipocytes: downregulation in human obesity and modulation by diet-induced weight loss. Int. J. Obes. 36 (2012), 1552–1557.
60. 60 Wessler, I., et al. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol. Ther. 77 (1998), 59–79.
61. 61 Yang, D., et al. miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression. J. Cell Sci. 125 (2012), 1673–1682.
62. 62 Lin, T., et al. Intensified vmPFC surveillance over PTSS under perturbed microRNA-608/AChE interaction. Transl. Psychiatry, 6, 2016, e801.
63. 63 Rossi, J., et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab. 13 (2011), 195–204.
64. 64 Sohn, J.W., et al. Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic preganglionic neurons. Cell 152 (2013), 612–619.
65. 65 Berglund, E.D., et al. Melanocortin 4 receptors in autonomic neurons regulate thermogenesis and glycemia. Nat. Neurosci. 17 (2014), 911–913.
66. 66 Yeo, G.S., et al. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum. Mol. Genet. 12 (2003), 561–574.
67. 67 Vaisse, C., et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 106 (2000), 253–262.
68. 68 Shibao, C., et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension 49 (2007), 27–33.
69. 69 Grassi, G., et al. Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea. J. Hypertens. 32 (2014), 383–388.
70. 70 Grizelj, I., et al. Reduced flow-and acetylcholine-induced dilations in visceral compared to subcutaneous adipose arterioles in human morbid obesity. Microcirculation 22 (2015), 44–53.
71. 71 Pelat, M., et al. Impaired atrial M2-cholinoceptor function in obesity-related hypertension. Hypertension 34 (1999), 1066–1072.
72. 72 Haddad el, B., Rousell, J., Regulation of the expression and function of the M2 muscarinic receptor. Trends Pharmacol. Sci. 19 (1998), 322–327.
73. 73 Rosoff, M.L., et al. Isolation and characterization of the chicken m2 acetylcholine receptor promoter region: induction of gene transcription by leukemia inhibitory factor and ciliary neurotrophic factor. Proc. Nat. Acad. Sci. U.S.A. 93 (1996), 14889–14894.
74. 74 Rao, A.A., et al. Exploring the role of BCHE in the onset of diabetes, obesity and neurological disorders. Bioinformation 8 (2012), 276–280.
75. 75 Boberg, D.R., et al. Molecular forms of butyrylcholinesterase and obesity. Genet. Mol. Biol. 33 (2010), 452–454.
76. 76 Baltimore, D., et al. MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9 (2008), 839–845.
77. 77 Soreq, H., Seidman, S., Acetylcholinesterase – new roles for an old actor. Nat. Rev. Neurosci. 2 (2001), 294–302.
78. 78 Nadorp, B., Soreq, H., Gut feeling: microRNA discriminators of the intestinal TLR9-cholinergic links. Int. Immunopharmacol. 29 (2015), 8–14.
79. 79 Shaltiel, G., et al. Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. Brain Struct. Funct. 218 (2013), 59–72.
80. 80 Pfau, M.L., Russo, S.J., Neuroinflammation regulates cognitive impairment in socially defeated mice. Trends Neurosci. 39 (2016), 353–355.
81. 81 Sun, Y., et al. MicroRNA-124 mediates the cholinergic anti-inflammatory action through inhibiting the production of pro-inflammatory cytokines. Cell Res. 23 (2013), 1270–1283.
82. 82 Nadorp, B., Soreq, H., Predicted overlapping microRNA regulators of acetylcholine packaging and degradation in neuroinflammation-related disorders. Front. Mol. Neurosci., 7, 2014, 9.
83. 83 Huang, X., et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics, 14, 2013, 319.
84. 84 Ross, S.A., Davis, C.D., The emerging role of microRNAs and nutrition in modulating health and disease. Annu. Rev. Nutr. 34 (2014), 305–336.
85. 85 Carlsson, L.M., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N. Engl. J. Med. 367 (2012), 695–704.
86. 86 Mabley, J.G., et al. Nicotine reduces the incidence of type I diabetes in mice. J. Pharmacol. Exp. Ther. 300 (2002), 876–881.
87. 87 Sheffrin, M., et al. Weight loss associated with cholinesterase inhibitors in individuals with dementia in a national healthcare system. J. Am. Geriatr. Soc. 63 (2015), 1512–1518.
88. 88 Abudayyeh, O.O., et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 2016, 10.1126/science.aaf5573 Published online June 2, 2016.
89. 89 Zhu, Y., et al. Evolutionary relationships between miRNA genes and their activity. BMC Genomics, 13, 2012, 718.
90. 90 Barbash, S., et al. Global coevolution of human microRNAs and their target genes. Mol. Biol. Evol. 31 (2014), 1237–1247.
91. 91 Plaisance, V., et al. MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J. Biol. Chem. 281 (2006), 26932–26942.
92. 92 Wang, Q., et al. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc. Nat. Acad. Sci. U.S.A. 105 (2008), 2889–2894.
93. 93 Kloting, N., et al. MicroRNA expression in human omental and subcutaneous adipose tissue. PloS ONE, 4, 2009, e4699.
94. 94 Heneghan, H.M., et al. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J. Clin. Endocrinol. Metab. 96 (2011), E846–E850.
95. 95 Doebele, C., et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 115 (2010), 4944–4950.
96. 96 He, L., et al. A microRNA polycistron as a potential human oncogene. Nature 435 (2005), 828–833.
97. 97 Davis, B.N., et al. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454 (2008), 56–61.
98. 98 Ji, R., et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ. Res. 100 (2007), 1579–1588.
99. 99 Chan, J.A., et al. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65 (2005), 6029–6033.
100. 100 Lorente-Cebrian, S., et al. MicroRNAs regulate human adipocyte lipolysis: effects of miR-145 are linked to TNF-alpha. PloS ONE, 9, 2014, e86800.
101. 101 Zhou, R., et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34 (2009), 1395–1405.
102. 102 Lovis, P., et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 57 (2008), 2728–2736.
103. 103 Parsons, M.J., et al. Using hippocampal microRNA expression differences between mouse inbred strains to characterise miRNA function. Mamm. Genome 19 (2008), 552–560.
104. 104 Makeyev, E.V., et al. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell 27 (2007), 435–448.
105. 105 Estep, M., et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 32 (2010), 487–497.
106. 106 Liu, X., et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ. Res. 104 (2009), 476–487.
107. 107 Meerson, A., et al. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-alpha. Diabetologia 56 (2013), 1971–1979.
108. 108 Ortega, F.J., et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PloS ONE, 5, 2010, e9022.
109. 109 Davis, B.N., et al. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J. Biol. Chem. 284 (2009), 3728–3738.
110. 110 Gerin, I., et al. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. Am. J. Physiology. Endocrinol. Metab. 299 (2010), E198–E206.
111. 111 Nagai, N., et al. Autonomic nervous system activity and the state and development of obesity in Japanese school children. Obes. Res. 11 (2003), 25–32.
112. 112 Southam, L., et al. Is the thrifty genotype hypothesis supported by evidence based on confirmed type 2 diabetes- and obesity-susceptibility variants?. Diabetologia 52 (2009), 1846–1851.
113. 113 Zhou, G., et al. Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2). J. Biol. Chem. 288 (2013), 11940–21198.
114. 114 Grundy, S.M., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler. Thromb. Vasc. Biol. 24 (2004), e13–e18, 10.1161/01.CIR.0000111245.75752.C6.